BB BIOVENTURES L P Form SC 13G/A February 13, 2006

OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2006 Estimated average burden hours per response...11

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

OSCIENT PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

68812R105

(CUSIP Number)

December 31, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
 o Rule 13d-1(c)

 b Rule 13d-1(d)
- * The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Page 1 of 11

CUSIP No. 68812R105 NAMES OF REPORTING PERSONS: BB BioVentures L.P. 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): 2 (a) o (b) þ SEC USE ONLY: 3 CITIZENSHIP OR PLACE OF ORGANIZATION: 4 Delaware SOLE VOTING POWER: 5 NUMBER OF 2,041,174 **SHARES** SHARED VOTING POWER: BENEFICIALLY OWNED BY 0 **EACH** SOLE DISPOSITIVE POWER: 7 REPORTING **PERSON** 2,041,174 WITH: SHARED DISPOSITIVE POWER:

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

8

9

2,041,174

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

11

2.6%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

PN

CUSIP No. 68812R105

9

NAMES OF REPORTING PERSONS: MPM BioVentures Parallel Fund, L.P. 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): 2 (a) o (b) þ SEC USE ONLY: 3 CITIZENSHIP OR PLACE OF ORGANIZATION: 4 Delaware SOLE VOTING POWER: 5 NUMBER OF 262,560 **SHARES** SHARED VOTING POWER: BENEFICIALLY OWNED BY 0 **EACH** SOLE DISPOSITIVE POWER: 7 REPORTING **PERSON** 262,560 WITH: SHARED DISPOSITIVE POWER: 8 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

262,560

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

11

0.3%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

PN

CUSIP No. 68812R105

9

NAMES OF REPORTING PERSONS: MPM Asset Management Investors 1998 LLC 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): 2 (a) o (b) þ SEC USE ONLY: 3 CITIZENSHIP OR PLACE OF ORGANIZATION: 4 Delaware SOLE VOTING POWER: 5 NUMBER OF 26,801 **SHARES** SHARED VOTING POWER: BENEFICIALLY OWNED BY 0 **EACH** SOLE DISPOSITIVE POWER: 7 REPORTING **PERSON** 26,801 WITH: SHARED DISPOSITIVE POWER: 8 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

26,801

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

11

0.03%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

OO

```
CUSIP No.
             68812R105
        NAMES OF REPORTING PERSONS:
        Ansbert Gadicke
  1
        I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
        CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  2
        (a) o
        (b) þ
        SEC USE ONLY:
  3
        CITIZENSHIP OR PLACE OF ORGANIZATION:
  4
        Delaware
                   SOLE VOTING POWER:
               5
                   0
 NUMBER OF
   SHARES
                   SHARED VOTING POWER:
BENEFICIALLY
  OWNED BY
                   2,330,535(1)
    EACH
                   SOLE DISPOSITIVE POWER:
               7
 REPORTING
   PERSON
                   0
    WITH:
                   SHARED DISPOSITIVE POWER:
               8
```

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

2,330,535(1)

2,330,535(1)

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

11

3.0%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

12

IN

(1) The shares are held as follows: 2,041,174 by BB BioVentures L.P. (BB Bioventures), 262,560 by MPM BioVentures Parallel Fund, L.P. (MPM Parallel) and 26,801 by MPM Asset Management Investors 1998 LLC (MPM Investors). BB BioVentures is under common control with MPM Parallel and MPM Investors. BAB BioVentures L.P. (BAB BV), BAB BioVentures NV and MPM BioVentures I LLC (BioVentures LLC) are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P. (BioVentures LP) and BioVentures LLC are the direct and indirect general partners of MPM Parallel. The Reporting person is a manager of BioVentures LLC and MPM Investors.

Page 5 of 11

```
CUSIP No.
             68812R105
        NAMES OF REPORTING PERSONS:
        Luke Evnin
  1
        I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
        CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  2
        (a) o
        (b) þ
        SEC USE ONLY:
  3
        CITIZENSHIP OR PLACE OF ORGANIZATION:
  4
        Delaware
                   SOLE VOTING POWER:
               5
 NUMBER OF
                   26,069(2)
   SHARES
                   SHARED VOTING POWER:
BENEFICIALLY
  OWNED BY
                   2,330,535(1)
    EACH
                   SOLE DISPOSITIVE POWER:
               7
 REPORTING
   PERSON
                   26,069(2)
    WITH:
                   SHARED DISPOSITIVE POWER:
```

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

8

9

2,330,535(1)

2,356,604(2)

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

11

3.1%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

12

IN

- (1) The shares are held as follows: 2,041,174 by BB BioVentures L.P. (BB Bioventures), 262,560 by MPM BioVentures Parallel Fund, L.P. (MPM Parallel) and 26,801 by MPM Asset Management Investors 1998 LLC (MPM Investors). BB BioVentures is under common control with MPM Parallel and MPM Investors. BAB BioVentures L.P. (BAB BV), BAB BioVentures NV and MPM BioVentures I LLC (BioVentures LLC) are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P. (BioVentures LP) and BioVentures LLC are the direct and indirect general partners of MPM Parallel. The Reporting person is a manager of BioVentures LLC and MPM Investors.
- (2) Includes 26,069 shares issuable pursuant to options exercisable within 60 days of December 31, 2005. Page 6 of 11

Item 1.

(a) Name of Issuer

Oscient Pharmaceuticals, Inc.

(b) Address of Issuer s Principal Executive Offices

1000 Winter Street

Suite 2200

Waltham, MA 02451

Item 2.

(a) Name of Person Filing

BB BioVentures, LP

MPM BioVentures Parallel Fund, LP

MPM Asset Management Investors 1998 LLC

Ansbert Gadicke

Luke Evnin

(b) Address of Principal Business Office or, if none, Residence

c/o MPM Capital L.P.

The John Hancock Tower

200 Clarendon Street, 54th Floor

Boston, MA 02116

(c) Citizenship

All entities were organized in Delaware and all individuals are United States citizens.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

68812R105

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

(a) Amount Beneficially Owned:

BB BioVentures, LP	2,041,174
MPM BioVentures Parallel Fund, LP	262,560
MPM Asset Management Investors 1998 LLC	26,801
Ansbert Gadicke	2,330,535(1)
Luke Evnin	2,356,604(1)(2)

Page 7 of 11

BB BioVentures, LP	2.6%
MPM BioVentures Parallel Fund, LP	0.3%
MPM Asset Management Investors 1998 LLC	0.03%
Ansbert Gadicke	3.0%
Luke Evnin	3.1%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

BB BioVentures, LP	2,041,174
MPM BioVentures Parallel Fund, LP	262,560
MPM Asset Management Investors 1998 LLC	26,801
Ansbert Gadicke	0
Luke Evnin	26,069(2)

(ii) Shared power to vote or to direct the vote

BB BioVentures, LP	0
MPM BioVentures Parallel Fund, LP	0
MPM Asset Management Investors 1998 LLC	0
Ansbert Gadicke	2,330,535(1)
Luke Evnin	2,356,604(1)(2)

(iii) Sole power to dispose or to direct the disposition of

BB BioVentures, LP	2,041,174
MPM BioVentures Parallel Fund, LP	262,560
MPM Asset Management Investors 1998 LLC	26,801
Ansbert Gadicke	0
Luke Evnin	26,069(2)

Page 8 of 11

(iv) Shared power to dispose or to direct the disposition of

BB BioVentures, LP	0
MPM BioVentures Parallel Fund, LP	0
MPM Asset Management Investors 1998 LLC	0
Ansbert Gadicke	2,330,535(1)
Luke Evnin	2,356,604(1)(2)

- (1) The shares are held as follows: 2,041,174 by BB BioVentures L.P. (BB Bioventures), 262,560 by MPM BioVentures Parallel Fund, L.P. (MPM Parallel) and 26,801 by MPM Asset Management Investors 1998 LLC (MPM Investors). BB BioVentures is under common control with MPM Parallel and MPM Investors. BAB BioVentures L.P. (BAB BV), BAB BioVentures NV and MPM BioVentures I LLC (BioVentures LLC) are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P. (BioVentures LP) and BioVentures LLC are the direct and indirect general partners of MPM Parallel. The Reporting person is a manager of BioVentures LLC and MPM Investors.
- (2) Includes 26,069 shares issuable pursuant to options exercisable within 60 days of December 31, 2005.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following b.

Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of a Group

Not Applicable

Item 10. Certification

Not Applicable

Page 9 of 11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 9, 2006

BB BIOVENTURES L.P. MPM BIOVENTURES PARALLEL FUND, L.P.

By: BAB BioVentures L.P., By: MPM BioVentures I LP, its General Partner its General Partner

By: BAB BioVentures N.V., By: MPM BioVentures I LLC, its General Partner its General Partner

By: \s\ Ansbert Gadicke By: \s\ Luke Evnin

Name: Ansbert Gadicke
Name: Luke B. Evnin
Title: Manager
Title: Manager

MPM ASSET MANAGEMENT INVESTORS

1998 LLC

By: \s\ Luke Evnin

Name: Luke B. Evnin By: \s\ Ansbert Gadicke

Title: Manager Name: Ansbert Gadicke

By: \s\ Luke Evnin

Name: Luke B. Evnin

Page 10 of 11

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Oscient Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 9th day of February, 2006.

BB BIOVENTURES L.P. MPM BIOVENTURES PARALLEL FUND, L.P.

By: BAB BioVentures L.P., its General Partner

By: MPM BioVentures I LP, its General Partner

By: BAB BioVentures N.V., By: MPM BioVentures I LLC, its General Partner its General Partner

By: \s\ Ansbert Gadicke By: \s\ Luke Evnin

Name: Ansbert Gadicke
Name: Luke B. Evnin
Title: Manager
Title: Manager

MPM ASSET MANAGEMENT INVESTORS 1998 LLC

By: \s\ Luke Evnin

Name: Luke B. Evnin By: \s\ Ansbert Gadicke

Title: Manager Name: Ansbert Gadicke

By: \s\ Luke Evnin

Name: Luke B. Evnin

Page 11 of 11